Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587
This study is recruiting at 10 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity
- Overweight
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novo Nordisk A/S
- Last updated on ClinicalTrials.gov
- June 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Diablo Clinical Research, Inc. · Walnut Creek, CA
Florida · 4
- Northeast Research Institute · Fleming Island, FL
- Jacksonville Ctr For Clin Res · Jacksonville, FL
- Center for Diab,Obes & Metab · Pembroke Pines, FL
- Encore Medical Research of Weston · Weston, FL
North Carolina · 2
- Monroe Biomedical Research, LLC · Monroe, NC
- Accellacare · Wilmington, NC
Tennessee · 1
- Holston Medical Group_Bristol · Bristol, TN
Texas · 2
- Amarillo Medical Specialists · Amarillo, TX
- Elligo Clin Res Centre · Austin, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.